Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioblastoma 52Brain Neoplasms 28Glioma 22Gliosarcoma 19Melanoma 18Astrocytoma 17Central Nervous System Neoplasms 11Oligodendroglioma 10Neoplasms 9Neoplasm Metastasis 8Recurrence 6Carcinoma, Non-Small-Cell Lung 5Neuroblastoma 4Lymphoma 4Ependymoma 4Diffuse Intrinsic Pontine Glioma 3Breast Neoplasms 3Sarcoma, Ewing 2Neurologic Manifestations 2Neuroectodermal Tumors, Primitive 2Neoplasms, Second Primary 2Meningeal Carcinomatosis 2Medulloblastoma 2Bone Neoplasms 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Tetanus 1Spinal Cord Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Recurrent 1

Interventions

Temozolomide 2Therapeutics 1Sorafenib 1Irinotecan 1Immunoglobulins 1Cytidine Triphosphate 1Bevacizumab 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neurologic Manifestations × Temozolomide × Clear all
NCT02343549 2022-11-03

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Wake Forest University Health Sciences

Phase 2 Terminated
13 enrolled 23 charts
CNS

Brain Neoplasms, Neurologic Manifestations

NCT00365222 2009-01-22

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
1 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Neurologic Manifestations, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡